1. Home
  2. PAHC vs NVAX Comparison

PAHC vs NVAX Comparison

Compare PAHC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAHC
  • NVAX
  • Stock Information
  • Founded
  • PAHC 1946
  • NVAX 1987
  • Country
  • PAHC United States
  • NVAX United States
  • Employees
  • PAHC N/A
  • NVAX N/A
  • Industry
  • PAHC Biotechnology: Pharmaceutical Preparations
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PAHC Health Care
  • NVAX Health Care
  • Exchange
  • PAHC Nasdaq
  • NVAX Nasdaq
  • Market Cap
  • PAHC 1.5B
  • NVAX 1.4B
  • IPO Year
  • PAHC 2014
  • NVAX 1995
  • Fundamental
  • Price
  • PAHC $43.32
  • NVAX $7.90
  • Analyst Decision
  • PAHC Hold
  • NVAX Hold
  • Analyst Count
  • PAHC 4
  • NVAX 6
  • Target Price
  • PAHC $27.50
  • NVAX $11.33
  • AVG Volume (30 Days)
  • PAHC 239.8K
  • NVAX 4.2M
  • Earning Date
  • PAHC 11-05-2025
  • NVAX 11-06-2025
  • Dividend Yield
  • PAHC 1.11%
  • NVAX N/A
  • EPS Growth
  • PAHC 1895.04
  • NVAX N/A
  • EPS
  • PAHC 1.19
  • NVAX 2.54
  • Revenue
  • PAHC $1,296,215,000.00
  • NVAX $1,078,718,000.00
  • Revenue This Year
  • PAHC $14.80
  • NVAX $61.25
  • Revenue Next Year
  • PAHC $3.16
  • NVAX N/A
  • P/E Ratio
  • PAHC $36.45
  • NVAX $3.11
  • Revenue Growth
  • PAHC 27.37
  • NVAX 9.22
  • 52 Week Low
  • PAHC $16.16
  • NVAX $5.01
  • 52 Week High
  • PAHC $44.35
  • NVAX $11.55
  • Technical
  • Relative Strength Index (RSI)
  • PAHC 67.28
  • NVAX 39.99
  • Support Level
  • PAHC $40.63
  • NVAX $8.25
  • Resistance Level
  • PAHC $42.55
  • NVAX $8.66
  • Average True Range (ATR)
  • PAHC 1.93
  • NVAX 0.38
  • MACD
  • PAHC 0.15
  • NVAX -0.07
  • Stochastic Oscillator
  • PAHC 85.03
  • NVAX 1.32

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: